Vaxcyte Inc. is a vaccine company. The Company is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes pneumococcal conjugate vaccine (PCV) candidates. Its lead vaccine candidate is VAX-24, a 24-valent investigational PCV. Its pipeline also includes VAX-XP, VAX-A1 and VAX-PG. The Company's second PCV, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. VAX-PG is being developed as a protein vaccine for the treatment of periodontitis.
Number of employees : 58 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Fidelity Management & Research Co. LLC ||7,504,449||
|TPG Group Holdings (SBS) Advisors, Inc. ||4,558,475||
|Abingworth LLP ||4,168,718||
|Janus Capital Management LLC ||4,116,959||
|RA Capital Management LP ||3,865,808||
|Longitude Capital Management Co. LLC ||3,106,350||
|The Vanguard Group, Inc. ||2,791,613||
|Roche Holding AG ||2,587,754||
|Frazier Management LLC ||2,309,554||
|Medicxi Ventures (Jersey) Ltd. ||1,887,478||
|Company contact information|
GlaxoSmithKline : Former U.S. govt vaccine chief exits two drug developers after GSK harassment claim
Sector Bio Therapeutic Drugs
Connections : Vaxcyte, Inc.